Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yisaipu plus traditional Chinese medicine for rheumatoid arthritis after csDMARD failure
ChiCTR1900026270Phase 4Not yet recruiting
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Apr 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of etanercept in rheumatoid arthritis (RA) (3 arms), sponsored by China Academy of Chinese Medical Sciences. Primary endpoints: Low disease activity, Disease Activity Score in 28 joints and 4 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
etanercept
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR1900026270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026270.